TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23872125

Group type: EXPERIMENTAL
Intervention: C500 (C0+500 g/t aflatoxin biodegradation preparations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C1000 (C0+1000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M500 (M0+500 g/t aflatoxin biodegradation preparations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M1000 (M0+1000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M2000 (M0+2000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60

Group type: COMPARATOR
Intervention: C0 (basal diet)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M0 (basal diet containing moldy peanut meal)
Number of subjects: 60
Study: 21674848

Group type: COMPARATOR
Intervention: gabapentin
Number of subjects: 75

Group type: COMPARATOR
Intervention: gabapentin-NSAID
Number of subjects: 75

Group type: COMPARATOR
Intervention: gabapentin-NSAID-morphine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: multimodal therapy (gabapentin-NSAID-morphine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: multimodal therapy
Number of subjects: 75
Study: 19194671

Group type: EXPERIMENTAL
Intervention: Dynamic splinting adjunct to botulinum toxin type-A and manual therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (botulinum toxin type-A and manual therapy)
Number of subjects: 30
Study: 16963261

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 15207941

Group type: EXPERIMENTAL
Intervention: Controlled lithium discontinuation (CLD) protocol
Number of subjects: 32
Study: 11041313

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.33, 0.65, 1.3 mg/70 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (5 and 10 mg/70 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both opioids
Number of subjects: 0
Study: 9347207

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (NSAID) after the first dose of misoprostol
Number of subjects: 416

Group type: COMPARATOR
Intervention: No nonsteroidal anti-inflammatory drug after the first dose of misoprostol
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Number of subjects: 416

Group type: COMPARATOR
Intervention: No nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Number of subjects: 416
Study: 8111210

Group type: EXPERIMENTAL
Intervention: Foot reflexotherapy (FR) plus conventional Western medicine (hypoglycemic agent)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Western medicine (hypoglycemic agent) only
Number of subjects: 32
Study: 3089360

Group type: EXPERIMENTAL
Intervention: Salt added to lentils (4.25 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salt added to bread (4.25 g)
Number of subjects: 6
Study: 29154602

Group type: EXPERIMENTAL
Intervention: Tobacco power wall behind the cashier
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tobacco power wall hidden behind an opaque wall
Number of subjects: 148
Study: 26189587

Group type: EXPERIMENTAL
Intervention: Triage nurse initiated radiography using the Ottawa Ankle Rules (OAR)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard triage
Number of subjects: 146
Study: 25267802

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebivolol in sildenafil responders
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebivolol in sildenafil nonresponders
Number of subjects: 20
Study: 22362559

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 1 mg/kg followed by TNK-tPA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Supplemental IV enoxaparin 0.3 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: No IV enoxaparin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.3 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.5 mg/kg
Number of subjects: 45
Study: 20035146

Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily
Number of subjects: 30
Study: 18694989

Group type: EXPERIMENTAL
Intervention: Retention specialist intervention with 3-day training and ongoing support
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retention specialist intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no retention specialist)
Number of subjects: 30
Study: 16350719

Group type: EXPERIMENTAL
Intervention: Methylprednisolone i.v. pulses followed by oral prednisone treatment (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anti-thyroid drugs (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy volunteers (Group III)
Number of subjects: 60
Study: 12045520

Group type: EXPERIMENTAL
Intervention: Patient global assessment
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Disability instruments and pain scale
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 294
Study: 10223240

Group type: EXPERIMENTAL
Intervention: Total skin electron beam radiation (32-40 Gy, 4-6 MeV electrons)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: More intense radiation (32-40 Gy, 4-6 MeV electrons)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total skin electron beam radiation
Number of subjects: 45
Study: 7878754

Group type: EXPERIMENTAL
Intervention: CsA-ME (microemulsion formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA-GC (corn oil-based soft gel cap)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CsA-ME
Number of subjects: 0
Study: 2228847

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g iv
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 666154

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory ECG monitoring
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Graded treadmill exercise
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined results of both tests
Number of subjects: 70
Study: 30497490

Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR) intervention
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control (no CCR)
Number of subjects: 454
Study: 26861007

Group type: EXPERIMENTAL
Intervention: IAP18
Number of subjects: 50

Group type: COMPARATOR
Intervention: IAP12
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IAP12 and IAP18
Number of subjects: 50
Study: 24885412

Group type: EXPERIMENTAL
Intervention: Active group received electrical stimulation on the tongue that they could perceive
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group used a device that did not provide a physiologically significant stimulus and was not perceivable
Number of subjects: 20
Study: 22547251

Group type: EXPERIMENTAL
Intervention: 4 kcal/kg per week
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 8 kcal/kg per week
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 12 kcal/kg per week
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control (nonexercise)
Number of subjects: 404
Study: 20333744

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser treatment
Number of subjects: 28
Study: 18319355

Group type: EXPERIMENTAL
Intervention: Supervised exercise for 3 months followed by 3 months of unsupervised exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supervised exercise for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise advice alone (control)
Number of subjects: 60
Study: 15813141

Group type: EXPERIMENTAL
Intervention: Permethrin-treated tents (0.4% permethrin)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Insect repellent
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Permethrin-treated tents
Number of subjects: 545
Study: 12421432

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10379481

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (one hour at a maximum of 60% oxygen consumption)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (healthy age-matched subjects)
Number of subjects: 6
Study: 8727946

Group type: EXPERIMENTAL
Intervention: Gelatin-sealed knitted Dacron prosthesis (GDP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsealed knitted Dacron prostheses (UDP)
Number of subjects: 50
Study: 1944909

Group type: EXPERIMENTAL
Intervention: Felbamate (2,300 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 56
Study: 6842003

Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole plus nystatin
Number of subjects: 62

Group type: COMPARATOR
Intervention: nalidixic acid plus nystatin
Number of subjects: 62
Study: 31583708

Group type: EXPERIMENTAL
Intervention: Smartphone-based exposure treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist condition (Control)
Number of subjects: 36
Study: 30506226

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) with precoated brackets (Group IV)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional two-step etch and primer method (CEM) with precoated brackets (Group II)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) with uncoated brackets (Group III)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional two-step etch and primer method (CEM) with uncoated brackets (Group I)
Number of subjects: 63
Study: 28231036

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% with dexamethasone 0.1%
Number of subjects: 68

Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% alone
Number of subjects: 68
Study: 25828372

Group type: EXPERIMENTAL
Intervention: BiOSS Expert stent
Number of subjects: 243

Group type: COMPARATOR
Intervention: regular drug-eluting stent (rDES)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Final kissing balloon (FKB) inflation in BiOSS Expert
Number of subjects: 243

Group type: COMPARATOR
Intervention: Final kissing balloon (FKB) inflation in rDES
Number of subjects: 243
Study: 25138273

Group type: EXPERIMENTAL
Intervention: Postoperative perineural ropivacaine 0.2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 22677235

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 98
Study: 20461537

Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 306

Group type: COMPARATOR
Intervention: Darn procedure
Number of subjects: 306
Study: 18694444

Group type: EXPERIMENTAL
Intervention: Transcutaneous electroacupuncture (TEA)
Number of subjects: 27
Study: 15699686

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study: 11943440

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic treatment B
Number of subjects: 0
Study: 10086650

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mesalazine 4 g/day
Number of subjects: 40
Study: 7722711

Group type: EXPERIMENTAL
Intervention: Atole (high energy and high protein supplement: 163 kcals/682 kJ and 11.5 g protein per cup or 180 mL)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Fresco (low energy, no protein supplement: 59 kcals/247 kJ in 180 mL)
Number of subjects: 832

Group type: COMPARATOR
Intervention: No supplement (immigrants, n = 144)
Number of subjects: 832
Study: 1723468

Group type: EXPERIMENTAL
Intervention: Nitrendipine once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrendipine twice daily
Number of subjects: 20
Study: 6342771

Group type: EXPERIMENTAL
Intervention: CCNU-VP (lomustine, vinblastine, and prednisone)
Number of subjects: 47

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CCNU-VP
Number of subjects: 47

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 47
Study: 31752522

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 52
Study: 29913229

Group type: EXPERIMENTAL
Intervention: Nebulized peppermint essential oil for 15 minutes
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nebulized eucalyptus essential oil for 15 minutes
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nebulized rosemary essential oil for 15 minutes
Number of subjects: 106

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 106
Study: 26786780

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) (Ex-9) infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral sitagliptin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined Ex-9-sitagliptin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24329045

Group type: EXPERIMENTAL
Intervention: Renewal group (change in toothbrush every 4 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-renewal group (continuous use for 6 months)
Number of subjects: 96
Study: 18347838

Group type: EXPERIMENTAL
Intervention: DdeI polymorphism (homozygote T/T allele)
Number of subjects: 104

Group type: COMPARATOR
Intervention: MnlI and TaiI polymorphisms
Number of subjects: 104
Study: 15581125

Group type: EXPERIMENTAL
Intervention: Focused dimension on person in person-location pairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfocused dimension on location in person-location pairs
Number of subjects: 0
Study: 11044759

Group type: EXPERIMENTAL
Intervention: Diclectin (doxylamine-B6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (other pharmacological agents)
Number of subjects: 0
Study: 9048275

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8513519

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular Meperidine (IM)
Number of subjects: 40
Study: 2950914

Group type: EXPERIMENTAL
Intervention: Topical ketoconazole shampoo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30252149

Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 7266

Group type: COMPARATOR
Intervention: Shorter-duration enoxaparin
Number of subjects: 7266
Study: 28968858

Group type: EXPERIMENTAL
Intervention: 33% tapering TNFi
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 66% tapering TNFi
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (constant TNFi)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 33% tapering TNFi (months 6-12)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 66% tapering TNFi (months 6-12)
Number of subjects: 97
Study: 26659791

Group type: EXPERIMENTAL
Intervention: sifalimumab (200-1200 mg) administered intravenously every 4 weeks for 52 weeks
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: fixed dosing of sifalimumab
Number of subjects: 298
Study: 24507941

Group type: EXPERIMENTAL
Intervention: Purified antithrombin (5000 IU in three administrations)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22973178

Group type: EXPERIMENTAL
Intervention: Surgical pleth index (SPI) during propofol-remifentanil anaesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surgical pleth index (SPI)
Number of subjects: 80
Study: 19571155

Group type: EXPERIMENTAL
Intervention: Cinnamon extract (Cinnulin PF) 250 mg, two times per day for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17341711

Group type: EXPERIMENTAL
Intervention: Atkins diet
Number of subjects: 311

Group type: COMPARATOR
Intervention: Zone diet
Number of subjects: 311

Group type: COMPARATOR
Intervention: LEARN diet
Number of subjects: 311

Group type: COMPARATOR
Intervention: Ornish diet
Number of subjects: 311
Study: 15059043

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 10 days
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 5 days
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg (single-dose study)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (first week) followed by oral esomeprazole
Number of subjects: 246
Study: 11678744

Group type: EXPERIMENTAL
Intervention: Laparoscopic dismembered pyeloplasty
Number of subjects: 50
Study: 9141424

Group type: EXPERIMENTAL
Intervention: Banding ligation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 71
Study: 7530677

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice a day until ANC was 1,000/microliters (Group I, n=29)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: G‐CSF from Day 2 until ANC was greater than 10,000/microliters (Group II, n=15)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No prophylaxis (Group III, n=18)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with G‐CSF prophylaxis (n=24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin only (n=3)
Number of subjects: 62
Study: 3652622

Group type: EXPERIMENTAL
Intervention: Intravenous frusemide (30 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral indomethacin (100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral carbidopa (100 mg)
Number of subjects: 15
Study: 31667685

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29604502

Group type: EXPERIMENTAL
Intervention: Implicit encouragement (backchanneling, use of children's names)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Putative confession (telling children that a suspect 'told me everything that happened and wants you to tell the truth')
Number of subjects: 143

Group type: COMPARATOR
Intervention: Implicit encouragement
Number of subjects: 143

Group type: COMPARATOR
Intervention: Putative confession
Number of subjects: 143
Study: 27279471

Group type: COMPARATOR
Intervention: High-dose RO extract (HRE) 1800 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-dose RO extract (LRE) 900 mg/day
Number of subjects: 44
Study: 24461574

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1169
Study: 23733165

Group type: EXPERIMENTAL
Intervention: Monopolar spray coagulation (Group A)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA) application (Group B)
Number of subjects: 246
Study: 20419973

Group type: EXPERIMENTAL
Intervention: Intralesional injection of verapamil every 14 days for 6 months
Number of subjects: 16
Study: 17728193

Group type: EXPERIMENTAL
Intervention: Denufosol
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 16882525

Group type: EXPERIMENTAL
Intervention: Water treatment (active)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (no water treatment)
Number of subjects: 0
Study: 14594792

Group type: EXPERIMENTAL
Intervention: School-based multicomponent intervention (dietary change, increased physical activity, classroom curriculum, family involvement)
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1704
Study: 11076816

Group type: EXPERIMENTAL
Intervention: Continuous prostacyclin infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study: 8823067

Group type: EXPERIMENTAL
Intervention: Leaving a message on answering machines
Number of subjects: 1323

Group type: COMPARATOR
Intervention: No message left (Control)
Number of subjects: 1323
Study: 1426656

Group type: COMPARATOR
Intervention: Immunomodulators
Number of subjects: 15
Study: 3901764

Group type: EXPERIMENTAL
Intervention: Prepidil gel (0.5 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 59
Study: 31215837

Group type: EXPERIMENTAL
Intervention: Online educational modules, community forum, communication with a lifestyle coach
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group received internet links to CVD risk reduction information
Number of subjects: 151
Study: 29526233

Group type: EXPERIMENTAL
Intervention: LooH with a spiritual context
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LooH without a spiritual context
Number of subjects: 3

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 3
Study: 26423685

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Axitinib plus Candesartan
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: No treatment after Axitinib
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Candesartan (Control)
Number of subjects: 35
Study: 24776785

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA intensity)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA intensity)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 22826137

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 41